Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.

Kirit M Ardeshna; Wendi Qian; Paul Smith; Nivette Braganca; Lisa Lowry; Pip Patrick; June Warden; Lindsey Stevens; Christopher F E Pocock; Fiona Miall; David Cunningham; John Davies; Andrew Jack; Richard Stephens; Jan Walewski; Burhan Ferhanoglu; Ken Bradstock; David C Linch

首页> 外文期刊>The lancet oncology >Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.

【24h】

Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.

机译：利妥昔单抗与观察和等待方法治疗晚期，无症状，非大块性滤泡性淋巴瘤的患者：一项开放标签的3期随机试验。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Cancer Research UK, Lymphoma Research Trust, Lymphoma Association, and Roche.

机译：英国癌症研究，淋巴瘤研究基金会，淋巴瘤协会和罗氏。

著录项

来源
《The lancet oncology》 |2014年第4期|共12页
作者
Kirit M Ardeshna; Wendi Qian; Paul Smith; Nivette Braganca; Lisa Lowry; Pip Patrick; June Warden; Lindsey Stevens; Christopher F E Pocock; Fiona Miall; David Cunningham; John Davies; Andrew Jack; Richard Stephens; Jan Walewski; Burhan Ferhanoglu; Ken Bradstock; David C Linch;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. [J] . Kirit M Ardeshna, Wendi Qian, Paul Smith, The lancet oncology . 2014,第4期

机译：利妥昔单抗与观察和等待方法治疗晚期，无症状，非大块性滤泡性淋巴瘤的患者：一项开放标签的3期随机试验。
2. Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis [J] . Prica, A., Chan, Cancer: A Journal of the American Cancer Society . 2015,第15期

机译：前线利妥昔单抗单药诱导与无症状晚期滤泡性淋巴瘤的观察和等待方法：成本效益分析
3. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. [J] . Recher C, Coiffier B, Haioun C, The Lancet . 2011,第9806期

机译：含有ACVBP Plus rituximab的增强化疗与标准CheCh Plus Rituximab用于治疗弥漫性大B细胞淋巴瘤（LNH03-2B）：开放标签随机相3试验。
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. Bortezomib plus rituximab versus rituximab in patients with high-risk relapsed rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial [O] . Pier Luigi Zinzani, Nuriet K Khuageva, Huaqing Wang, 2012

机译：硼替佐米联合利妥昔单抗与利妥昔单抗治疗高危复发未接受利妥昔单抗或利妥昔单抗敏感的滤泡性淋巴瘤的患者：一项3期随机试验的亚组分析
6. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. [O] . Récher, Christian, Coiffier, Bertrand, Haioun, Corinne, 2011

机译：ACVBP加利妥昔单抗与标准CHOP加利妥昔单抗强化化疗治疗弥漫性大B细胞淋巴瘤（LNH03-2B）：一项开放标签的随机3期试验。

Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.

摘要

著录项

相似文献

相关主题

期刊订阅